Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

PR Kalra, J Moon, AJ Coats

Research output: Contribution to journalArticle

272 Citations (Scopus)
Original languageEnglish
Pages (from-to)195-197
Number of pages3
JournalAmerican Heart Journal
Issue number2-3
Publication statusPublished - 2002

Cite this